News Center

Home page

Peak Report

News reports

Jianfeng Group Lin2016 -029 (Announcement on Progress of Subsidiary's Foreign Investment)

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2016-029

Bond Abbreviation: 13 Peak 01 Bond Code: 122227

Bond Abbreviation: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Progress of Subsidiary's Foreign Investment

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Basic Information on Foreign Investment in 1.

On July 12, 2016 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, and Germany Gefu Pharmaceutical Co., Ltd. (hereinafter referred to as "Gefu Pharmaceutical"), Zhuhai Hengqin Deyunjia International Trade Co., Ltd. (hereinafter referred to: de Yunjia) signed the "Sino-foreign Joint Venture Contract" and jointly funded the establishment of a Sino-foreign joint venture in Jinhua City, Zhejiang Province, China, committed to building a pharmaceutical company for infants and children. The Chinese name of the joint venture company is: Zhejiang Jindel Baby Pharmaceutical Co., Ltd. The registered capital of the joint venture company is RMB 20 million, of which: Jianfeng Pharmaceutical contributed RMB 11 million in cash, Ge Fu Pharmaceutical contributed RMB 5 million in the evaluation of intellectual property rights of proprietary technology, and Deyunjia contributed RMB 4 million in cash.

For details, please refer to 2016 -Lin 2016-026 "Announcement on Foreign Investment of Subsidiaries" published by the company in the designated information disclosure media "shanghai securities news", "china securities journal" and the website of Shanghai Stock Exchange (www.sse.com.cn ) on July 13, 40.

Progress of 2. Foreign Investment

After the signing of the Sino-Foreign Joint Venture Contract, the parties to the cooperation have applied to the relevant departments in accordance with relevant national laws, regulations and relevant government regulations and obtained the Approval Certificate for the People's Republic of China Foreign-invested Enterprises and the Business License.

The main registration items of the "Business License" are as follows:

Name: Zhejiang Jindel Baby Drug Co., Ltd.

Unified Social Credit Code: 91330700MA28E8DU4L

Type: Limited Liability Company (

Sino-foreign Joint Venture)

Domicile: legal Representative of

, 3rd Floor, X02 Office Quality Inspection Building, No. 58

, Gaofan Section, Tangxi Town, Wucheng District, Jinhua City, Zhejiang Province: Jiang Xiaomeng

Registered Capital: RMB 20 Million Yuan

Date of Establishment: August 30, 2016

Business Term: 2016

from August 30 to August 29, 2046

Scope of business: drug research and development, drug production (see "Drug Production License" for the specific scope), drug business (see "Drug Business License" for the specific scope), import and export of health products. (For projects subject to approval according to law, business activities can only be carried out after approval by relevant departments)

As of the date of this announcement, the cooperating parties have not yet made capital contributions.

3. Reference Document

Copy of Business License of Zhejiang Jindal Baby Pharmaceutical Co., Ltd. and Approval Certificate of the People's Republic of China Foreign Investment Enterprise.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

September 2, 2016

More information

2022 China's Top 100 Building Materials Enterprises 2022 China's Top 100 Cement Clinker Production Capacity Peak even on two authoritative lists

In March, the authoritative organization of the cement industry successively released two series of lists of China's top 500 building materials enterprises in 2022 and China's top 100 cement clinker production capacity in 2022. Jianfeng Group ranked among the "top 100" in the two lists ". The list of China's top 500 building materials enterprises was officially released in early March. This series of lists was selected by the China Building Materials Enterprise Management Association. Through more than 20 years of comprehensive data research on China's building materials industry, referring to international practices, the rankings are based on the company's annual operating income., Cement products, building ceramics, waterproof materials, aluminum-plastic profiles, coatings, glass, building materials equipment manufacturing and other sub-industries related to building materials. Jianfeng Group ranks 96th among the companies on the list and 27th among the cement manufacturers on the list. On March 16, the awarding ceremony of 2022 China's top 100 cement clinker production capacity list was held in Hangzhou. This series of lists is released by China Cement Network, an authoritative organization in China's cement industry. The ranking is based on the total production capacity (excluding the production capacity of other kiln types and grinding stations) of new dry clinker production lines completed and put into operation by Chinese cement enterprises in China as of December 31, 2022. The data statistics are calculated based on the design production capacity and 310 days of annual operation. Jianfeng Group ranked 53rd with an annual design capacity of 3.627 million tons. (this newspaper reporter)

2023

03-21

Company sends off retired employees

On the morning of February 22, the trade union of the group company held a simple and warm farewell party for retired employees in 2021-2022. More than 50 retired employees gathered together to discuss and exchange with Jiang Xiaomeng and other group leaders.

2023

03-04

On the first day of the new year, group leaders went to the grassroots level.

On January 29, the first day of work after the Spring Festival holiday, the leaders of the group company made a video connection to subordinate enterprises stationed abroad, and separately visited the gold enterprises to learn about the resumption of work and put forward requirements for the implementation of the work plan for the new year.

2023

02-17

Group Companies Commend 2022 Advanced

On the morning of January 18, the group company held the 2022 annual summary commendation meeting to review the work of the previous year, make arrangements for the work in 2023, sign the 2023 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2022 advanced collectives and individuals.

2023

01-29

Jiang Xiaomeng re-elected chairman of the Municipal Federation of Industry and Commerce

On December 24, 2022, the Jinhua Federation of Industry and Commerce (General Chamber of Commerce) held the seventh member representative meeting. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, was re-elected as the chairman of the Municipal Federation of Industry and Commerce at this meeting.

2023

01-12

Peak Pharmaceutical Donates Epidemic Prevention Materials

Since the optimization and adjustment of the new crown infection epidemic management policy, there has been an explosive growth of infected people in the country, and the pressure on the supply of related materials has increased sharply. Before and after New Year's Day, the company has twice organized epidemic prevention materials, through the Jinhua City Charity Federation, Jinhua City Economic and Technological Development Zone Charity Federation targeted donations, a total value of more than 200,000 yuan.

2023

01-12

< 1 2 3 4...61 > 跳转到页